Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

Go back to Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
INSMED (NASDAQ: INSM) Delayed: 94.84 +0.80 (0.85%)
Previous Close $94.04    52 Week High $19.30 
Open $93.50    52 Week Low $9.02 
Day High $95.59    P/E N/A 
Day Low $93.33    EPS $-1.69 
Volume 2,132,639